

REMARKS

The Applicants respectfully request reconsideration in view of the following remarks and amendments. Claims 1-6 are amended. Claims 7-14 are canceled. Accordingly, claims 1-6 are pending in the application.

I. Claims Rejected Under 35 U.S.C. § 103

Claims 1-14 stand rejected under 35 U.S.C. § 103(a) as being obvious over European Patent No. EP0638184 B1 issued to Lerche et al. (hereinafter “Lerche”) in view of U.S. Patent Publication No. 2002/132607 filed by Castell et al. (hereinafter “Castell”) in view of U.S. Patent No. 6,480,880 filed by Groenendaal et al. (hereinafter “Groenendaal”).

The virus monitoring unit of the present invention is configured to check virus infection of data received from a mobile terminal and cure the data to inactivate the virus if the data is infected with virus. And then, the cured data is transmitted to another mobile terminal. For example, paragraph [0029] of the Specification states the following:

[0029] Then, it is determined whether or not a virus is found or detected in the data at step S202. If a virus is detected in the data, information (e.g., identity) of the virus is analyzed at step S203. A virus vaccine program suitable for an identified virus is read from the DB 131 at step S204. The virus in data inactivated or cured by using the read virus vaccine program at step S205. Then, the cured data is transmitted to a destination mobile terminal, and the virus monitoring unit 132 notifies the mobile stations 111 to 114 of virus infection at step S206. The mobile terminals which receive the notification perform operation of inactivating or curing the virus therein at step S207. (emphasis added).

Thus, the virus monitoring unit of the present invention can prevent a mobile terminal from transmitting virus-infected data to other mobile terminals.

Claim 1, as amended, recites the elements of “a virus monitoring unit associated with the mobile communication system, for checking virus infection of data *received from a first mobile terminal*, analyzing virus information, choosing one of virus vaccine programs that are stored in the database and *curing the data received from the first mobile terminal to inactivate the virus, wherein the data is transmitted to a second mobile terminal after the curing*” (emphasis added). As mentioned above, support for the amendment may be found, for example, in paragraph [0029] of the Specification. Lerche fails to teach or suggest these elements. In contrast, Lerche

discloses a network adaptor being connected to a computer which together with the adaptor can perform scanning of all files on the network, carry out a recognition of virus signatures in the files and provide information on the place of origin of infected data. See Lerche, page 2, lines 24-31. The network adaptor of Lerche may transmit a so-called “vaccine” to personal computers located in the network so that the personal computer can erase a virus program with the received vaccine. See Lerche, page 2, lines 32-35. However, the network adaptor of Lerche does not operate to cure the data received from a personal computer and transmit the cured data to another personal computer as required by claim 1. Thus, the effect of the present invention that prevents a mobile terminal from transmitting virus-infected data to other mobile terminals is not taught or suggested by Lerche. Consequently, in view of at least these foregoing reasons, Lerche fails to teach or suggest each element of claim 1.

In addition, Castell and Groenendaal fail to teach or suggest the missing elements. In particular, Castell and Groenendaal do not teach or suggest the elements of preventing a mobile terminal from transmitting virus-infected data to other mobile terminals as required by the claim. Thus, for at least these reasons, Lerche in view of Castell in further view of Groenendaal fails to teach or suggest each element of claim 1. Further, dependent claims 2-4 are patentable over the cited art because each of these claims depends from base claim 1. Accordingly, reconsideration and withdrawal of the rejection of claims 1-4 are respectfully requested.

In regard to claim 5, this claim, as amended, recites analogous limitations to those in claim 1. Thus, for at least the reasons mentioned in connection with claim 1, Lerche in view of Castell in further view of Groenendaal fails to teach or suggest each element of claim 5. In addition, claim 6 is patentable over the cited art because of its dependency on claim 5. Accordingly, reconsideration and withdrawal of the rejection of claims 5 and 6 are respectfully requested.

With respect to claims 7-14, these claims are canceled. Thus, the Examiner’s rejection is moot.

CONCLUSION


In view of the foregoing, it is believed that all claims now pending patentably define the subject invention over the prior art of record, and are in condition for allowance and such action is earnestly solicited at the earliest possible date. If the Examiner believes that a telephone conference would be useful in moving the application forward to allowance, the Examiner is encouraged to contact the undersigned at (310) 207 3800.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP


Dated: 11/28, 2007

1279 Oakmead Parkway
Sunnyvale, CA 94085-4040
(310) 207-3800


Eric S. Hyman Reg. No. 30,139

CERTIFICATE OF MAILING:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 28, 2007.

 11-28-07
Melissa Stead November 28, 2007